# ATR inhibitor payloads

Source: https://onco.cc/terms/atr-inhibitor-payloads/  
OnCo record `atr-inhibitor-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An ATR inhibitor blocks a checkpoint that helps cells survive stress while copying DNA. Combining it with a DNA-damaging payload on one antibody is being tested in early research.

## Summary

CLIO-8221 carries exatecan and berzosertib, pairing TOP1-mediated damage with ATR checkpoint inhibition. The primary trial-design abstract describes preclinical activity and the planned assessment of safety, dosing and activity in people. The direct registry records a phase 1/2 trial. These sources establish the construct and its evaluation, not comparative benefit or a validated biomarker for choosing it after TOP1 treatment.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: berzosertib payload; TOP1 plus ATR dual payload; CLIO-8221 payloads

## Sources

- CLIO-8221 trial-design abstract (2026): https://doi.org/10.1200/JCO.2026.44.16_suppl.TPS3162
- ClinicalTrials.gov: NCT07300943: https://clinicaltrials.gov/study/NCT07300943

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/)
- terms: [DNA damage response inhibitor payloads](https://onco.cc/terms/ddr-inhibitor-payloads/), [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)
- trials: [Study in Advanced Solid Tumor Patients](https://onco.cc/trials/nct07300943/)

---
JSON: https://onco.cc/api/v1/entities/atr-inhibitor-payloads.json